Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVC NASDAQ:BNTC NASDAQ:CTOR NASDAQ:HRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$3.35-6.4%$2.18$0.40▼$5.48$56.89M0.37357,054 shs150,564 shsBNTCBenitec Biopharma$11.04-6.0%$14.01$7.05▼$17.15$308.18M0.3758,543 shs98,440 shsCTORCitius Oncology$1.53-4.4%$2.05$0.55▼$6.19$114.48M3.061.30 million shs573,376 shsHRTXHeron Therapeutics$1.93-3.5%$2.02$1.04▼$3.40$305.13M1.182.14 million shs1.06 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma-6.42%-15.62%+72.68%+291.81%+260.22%BNTCBenitec Biopharma-5.96%-13.62%-26.10%-19.71%+13.81%CTORCitius Oncology-4.38%-45.74%-1.29%+127.71%+152,999,900.00%HRTXHeron Therapeutics-3.50%-11.47%-3.50%+4.89%-44.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVCABVC BioPharma0.4205 of 5 stars0.03.00.00.02.40.80.0BNTCBenitec Biopharma1.6844 of 5 stars3.61.00.00.02.80.80.0CTORCitius Oncology1.6367 of 5 stars3.00.00.00.03.01.70.0HRTXHeron Therapeutics3.2132 of 5 stars3.50.00.04.20.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 0.00N/AN/AN/ABNTCBenitec Biopharma 3.20Buy$23.83115.88% UpsideCTORCitius Oncology 2.00Hold$3.0096.08% UpsideHRTXHeron Therapeutics 3.00Buy$5.00159.07% UpsideCurrent Analyst Ratings BreakdownLatest ABVC, BNTC, HRTX, and CTOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2025BNTCBenitec BiopharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy6/9/2025HRTXHeron TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/23/2025CTORCitius OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/23/2025CTORCitius OncologyMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/19/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.005/15/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$508.38K111.90N/AN/A$0.06 per share55.83BNTCBenitec BiopharmaN/AN/AN/AN/A$4.68 per shareN/ACTORCitius OncologyN/AN/AN/AN/A$0.64 per shareN/AHRTXHeron Therapeutics$144.29M2.04N/AN/A($0.22) per share-8.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$4.90M-$0.13N/A∞N/A-963.46%-29.62%-14.08%8/13/2025 (Estimated)BNTCBenitec Biopharma-$21.75M-$1.51N/AN/AN/AN/A-38.26%-35.71%9/25/2025 (Estimated)CTORCitius OncologyN/AN/A0.00∞N/AN/A-53.88%-18.86%N/AHRTXHeron Therapeutics-$13.58M-$0.06N/AN/AN/A-5.24%N/A-3.43%8/5/2025 (Estimated)Latest ABVC, BNTC, HRTX, and CTOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025HRTXHeron Therapeutics-$0.01N/AN/AN/A$38.08 millionN/A5/14/2025Q3 2025BNTCBenitec Biopharma-$0.36-$0.24+$0.12-$0.24N/AN/A5/14/2025Q2 2025CTORCitius Oncology-$0.09-$0.11-$0.02-$0.11$5.74 millionN/A5/6/2025Q1 2025HRTXHeron Therapeutics-$0.01$0.01+$0.02$0.01$37.08 million$38.90 million4/30/2025Q4 2024ABVCABVC BioPharmaN/A-$0.06N/A-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/ACTORCitius OncologyN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.220.22BNTCBenitec Biopharma0.0114.8014.80CTORCitius Oncology0.110.360.05HRTXHeron TherapeuticsN/A2.401.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%BNTCBenitec Biopharma52.19%CTORCitius Oncology70.52%HRTXHeron Therapeutics80.01%Insider OwnershipCompanyInsider OwnershipABVCABVC BioPharma17.10%BNTCBenitec Biopharma1.30%CTORCitius Oncology4.57%HRTXHeron Therapeutics5.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3016.98 million14.08 millionNot OptionableBNTCBenitec Biopharma2026.25 million25.91 millionNo DataCTORCitius OncologyN/A71.55 million68.28 millionN/AHRTXHeron Therapeutics300152.56 million143.62 millionOptionableABVC, BNTC, HRTX, and CTOR HeadlinesRecent News About These CompaniesHRTX Heron Therapeutics, Inc. - Seeking AlphaJuly 10, 2025 | seekingalpha.comHeron Therapeutics (NASDAQ:HRTX) Stock Crosses Above 200-Day Moving Average - Time to Sell?July 9, 2025 | marketbeat.comThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarJuly 7, 2025 | zacks.comThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarJuly 4, 2025 | zacks.comPalisade Capital Management LP Purchases 1,360,542 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)July 3, 2025 | marketbeat.comWith 60% institutional ownership, Heron Therapeutics, Inc. (NASDAQ:HRTX) is a favorite amongst the big gunsJuly 1, 2025 | finance.yahoo.comHeron Therapeutics (NASDAQ:HRTX) Stock Crosses Above Two Hundred Day Moving Average - What's Next?July 1, 2025 | marketbeat.comCongress Park Capital LLC Has $4.48 Million Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)June 20, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Stock Price Crosses Above 200 Day Moving Average - Here's WhyJune 19, 2025 | marketbeat.comHC Wainwright & Co. Initiates Coverage of Heron Therapeutics (HRTX) with Buy RecommendationJune 11, 2025 | msn.comResults: Heron Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesMay 9, 2025 | finance.yahoo.comEarnings call transcript: Heron Therapeutics beats Q1 2025 expectations, stock surgesMay 7, 2025 | investing.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2025 Earnings Call TranscriptMay 7, 2025 | insidermonkey.comHeron Therapeutics Inc (HRTX) Q1 2025 Earnings Call Highlights: Record EBITDA and Significant ...May 7, 2025 | finance.yahoo.comHeron Therapeutics, Inc.: Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate UpdatesMay 6, 2025 | finanznachrichten.deHeron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comCompared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key MetricsMay 6, 2025 | zacks.comHeron Therapeutics (HRTX) Q1 Earnings and Revenues Top EstimatesMay 6, 2025 | zacks.comHeron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate UpdatesMay 6, 2025 | prnewswire.comHeron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent LitigationsMay 6, 2025 | prnewswire.comHeron Therapeutics, Inc.: Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating OfficerApril 30, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABVC, BNTC, HRTX, and CTOR Company DescriptionsABVC BioPharma NASDAQ:ABVC$3.35 -0.23 (-6.42%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$3.36 +0.02 (+0.45%) As of 07/18/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Benitec Biopharma NASDAQ:BNTC$11.04 -0.70 (-5.96%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$11.06 +0.02 (+0.14%) As of 07/18/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Citius Oncology NASDAQ:CTOR$1.53 -0.07 (-4.38%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.54 +0.00 (+0.33%) As of 07/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Heron Therapeutics NASDAQ:HRTX$1.93 -0.07 (-3.50%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.94 +0.01 (+0.52%) As of 07/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
